Table 3.

Percent decreases in bone turnover markers after 48 weeks of treatment with risedronate according to the presence or absence of each component of metabolic syndrome

	Diabetes		Hypertension		Dyslipidemia
	Yes	No	Yes	No	Yes	No
NTX
N	44	682	214	512	242	484
Decrease rate (%)	25.5 ± 44.0	36.0 ± 37.6	35.7 ± 44.5	35.3 ± 35.0	36.5 ± 33.7	34.8 ± 40.1
Difference	−10.5		0.4		1.7
95 % confidence interval	−22.1–1.1		−5.6–6.5		−4.2–7.6
CTX
N	27	406	131	302	166	267
Decrease rate (%)	57.3 ± 28.9	55.1 ± 33.9	57.0 ± 25.0	54.5 ± 36.7	55.0 ± 39.5	55.4 ± 29.4
Difference	2.2		2.5		−0.4
95 % confidence interval	−10.9–15.3		−4.4–9.4		−6.9–6.1
BAP
N	27	405	131	301	166	266
Decrease rate (%)	33.7 ± 16.7	33.8 ± 20.9	31.6 ± 20.2	34.7 ± 20.8	32.7 ± 21.5	34.4 ± 20.1
Difference	−0.0		−3.1		−1.8
95 % confidence interval	−8.1–8.0		−7.3–1.2		−5.8–2.3

NTX N-terminal telopeptide of type 1 collagen, CTX C-terminal telopeptide of type 1 collagen, BAP bone-specific alkaline phosphatase